Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28711007 | 0.84 | MAPT (0.45) | MAPTACHESIGMAR1TMEM97 | |
| SCHEMBL4391046 | 0.83 | MAPT (0.47) | MAPTACHESIGMAR1TMEM97GAA | |
| SCHEMBL4401478 | 0.81 | MAPT (0.43) | MAPTACHESIGMAR1TMEM97 | |
| SCHEMBL5782146 | 0.80 | GRM6 (0.41) | ACHESIGMAR1TMEM97GAAGRM6 | |
| SCHEMBL5782725 | 0.78 | MAOB (0.52) | GAAGRM6 | |
| SCHEMBL5782723 | 0.78 | MAOB (0.52) | GAAGRM6 | |
| SCHEMBL6853255 | 0.75 | ACHE (0.56) | MAPTACHESIGMAR1GBA1KDM4E | |
| SCHEMBL20588229 | 0.75 | ACHE (0.56) | MAPTACHESIGMAR1GBA1KDM4E | |
| SCHEMBL24801996 | 0.73 | MAPT (0.44) | MAPTACHESIGMAR1TMEM97GAA | |
| SCHEMBL24802004 | 0.73 | MAPT (0.44) | MAPTACHESIGMAR1TMEM97GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| EP-3505171-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2019-07-03 | — | — | EP | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185479-A1 | BICYCLIC NITROGENATED HETEROCYCLIC COMPOUND | PDE7B, PDE3A, PDE7A | MAPT 2898/4885ACHE 244/4885SIGMAR1 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.